Latest Information Update: 03 Mar 2016
At a glance
- Originator InflaRx
- Class Monoclonal antibodies
- Mechanism of Action Complement C5a inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation
Most Recent Events
- 03 Mar 2016 Preclinical trials in Inflammation in Germany (unspecified route) before March 2016